272 related articles for article (PubMed ID: 1696353)
1. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1).
Neurath AR; Strick N
Mol Immunol; 1990 Jun; 27(6):539-49. PubMed ID: 1696353
[TBL] [Abstract][Full Text] [Related]
2. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
Neurath AR; Strick N; Lee ES
J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
[TBL] [Abstract][Full Text] [Related]
3. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)--II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef.
Neurath AR; Strick N; Kolbe H; Kieny MP; Girard M; Jiang S
Mol Immunol; 1991 Sep; 28(9):965-73. PubMed ID: 1717841
[TBL] [Abstract][Full Text] [Related]
4. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
[TBL] [Abstract][Full Text] [Related]
5. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.
Jiang SB; Lin K; Neurath AR
J Exp Med; 1991 Dec; 174(6):1557-63. PubMed ID: 1836013
[TBL] [Abstract][Full Text] [Related]
7. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactivity between autoimmune anti-U1 snRNP antibodies and neutralizing epitopes of HIV-1 gp120/41.
Douvas A; Takehana Y
AIDS Res Hum Retroviruses; 1994 Mar; 10(3):253-62. PubMed ID: 7517148
[TBL] [Abstract][Full Text] [Related]
9. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
10. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
Park EJ; Vujcic LK; Anand R; Theodore TS; Quinnan GV
J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
[TBL] [Abstract][Full Text] [Related]
11. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
12. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
Davis D; Stephens DM; Carne CA; Lachmann PJ
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
[TBL] [Abstract][Full Text] [Related]
13. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
Broliden PA; von Gegerfelt A; Clapham P; Rosen J; Fenyö EM; Wahren B; Broliden K
Proc Natl Acad Sci U S A; 1992 Jan; 89(2):461-5. PubMed ID: 1370580
[TBL] [Abstract][Full Text] [Related]
14. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
15. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
16. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
Grundner C; Li Y; Louder M; Mascola J; Yang X; Sodroski J; Wyatt R
Virology; 2005 Jan; 331(1):33-46. PubMed ID: 15582651
[TBL] [Abstract][Full Text] [Related]
18. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
[TBL] [Abstract][Full Text] [Related]
19. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
20. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
